Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.
作者信息
Duda Dan G, Heist Rebecca S, Sahani Dushyant V, Stylianopoulos Triantafyllos, Engelman Jeffrey A, Jain Rakesh K
机构信息
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
出版信息
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16.
Abstract
摘要
相似文献
1
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.对西科利尼等人的回复：利用数学建模预测癌症患者对抗血管生成疗法的反应。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16.
2
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.提高抗血管生成与化疗联合治疗的疗效：是时候借助数学建模支持了。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16.
3
In focus: non-small cell lung cancer: E1505.聚焦：非小细胞肺癌：E1505。
Clin Adv Hematol Oncol. 2007 Mar;5(3):206-8.
4
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
5
[Are antiangiogenic antibodies universal for solid tumor?].抗血管生成抗体对实体瘤是否具有普遍性？
Bull Cancer. 2007 Jul;94 Spec No:S191-6.
6
Angiogenesis inhibition in the treatment of lung cancer.血管生成抑制在肺癌治疗中的应用
Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2.
7
Antiangiogenic agents in breast cancer.乳腺癌中的抗血管生成药物。
Cancer Invest. 2007 Oct;25(7):518-26. doi: 10.1080/07357900701648516.
8
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.非小细胞肺癌中的化疗与抗血管生成药物
Clin Lung Cancer. 2007 Feb;8 Suppl 2:S68-73. doi: 10.3816/clc.2007.s.004.
9
Targeting tumor neovasculature in non-small-cell lung cancer.靶向非小细胞肺癌中的肿瘤新生血管。
Crit Rev Oncol Hematol. 2013 May;86(2):130-42. doi: 10.1016/j.critrevonc.2012.10.003. Epub 2012 Nov 15.
10
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?肺癌这个“派”能按血管生成切成不同“片”吗？
Clin Cancer Res. 2015 Dec 1;21(23):5188-90. doi: 10.1158/1078-0432.CCR-15-1180. Epub 2015 Jul 31.
本文引用的文献
1
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.提高抗血管生成与化疗联合治疗的疗效：是时候借助数学建模支持了。
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16.
2
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.卡铂和纳米白蛋白结合型紫杉醇抗VEGF治疗后肿瘤血管生成改善与肺癌患者生存率相关。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20.
3
Combining two strategies to improve perfusion and drug delivery in solid tumors.联合两种策略以改善实体瘤中的灌注和药物递送。
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18632-7. doi: 10.1073/pnas.1318415110. Epub 2013 Oct 28.
4
Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion.肿瘤血管生成、肿瘤生长和血液灌注的耦合建模。
J Theor Biol. 2011 Jun 21;279(1):90-101. doi: 10.1016/j.jtbi.2011.02.017. Epub 2011 Mar 12.
5
Structural adaptation and heterogeneity of normal and tumor microvascular networks.正常和肿瘤微血管网络的结构适应性与异质性
PLoS Comput Biol. 2009 May;5(5):e1000394. doi: 10.1371/journal.pcbi.1000394. Epub 2009 May 29.
6
Multiscale modelling and nonlinear simulation of vascular tumour growth.血管肿瘤生长的多尺度建模与非线性模拟
J Math Biol. 2009 Apr;58(4-5):765-98. doi: 10.1007/s00285-008-0216-9. Epub 2008 Sep 10.
Zotero 插件